EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis

Oguzcan Kinikoglu

Southern Clinics of Istanbul Eurasia · 2025 · 57-62

DOI: 10.14744/scie.2025.20092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Southern Clinics of Istanbul Eurasia, 2025. Verfasst von Oguzcan Kinikoglu. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the effectiveness and safety of CDK4/6 inhibitor therapy in patients aged ≥70 years diagnosed with hormone receptor-positive (HR+) HER2-negative metastatic breast cancer (MBC).Given the unique challenges faced by older adults due to comorbidities and potential treatment-related toxicities, this study aimed to provide insights into real-world outcomes in this population.

Methods

This retrospective, single-center analysis included 43 patients aged ≥70 years diagnosed with HR+ HER2-MBC who started CDK4/6 inhibitor treatment between May 2020 and December 2022.Data were collected from medical records, including demographics, ECOG performance status, treatment details, and adverse events.Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis, whereas subgroup comparisons were performed using log-rank tests.Cox proportional hazard models were used to identify the factors associated with PFS and OS.

Results

The median age was 76.7 years, and 46.5% of the patients presented with de novo metastasis.CDK4/6 inhibitors were administered as first-line treatment in 41.9% of patients, second-line therapy in 46.5 %, and third-line therapy in 11.6 %.The median PFS was 16.0 months, with patients with ECOG PS 0 or 1 achieving significantly longer PFS (20.0 months) than those with ECOG PS≥2 (5.8 months, p

Zitieren

APA

Kinikoglu, O. (2025). Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis. Southern Clinics of Istanbul Eurasia, 57-62. https://doi.org/10.14744/scie.2025.20092

Vancouver

Kinikoglu O. Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis. Southern Clinics of Istanbul Eurasia. 2025:57-62. doi:10.14744/scie.2025.20092

BibTeX
@article{Kinikoglu2025,
  author = {Kinikoglu, Oguzcan},
  title = {Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis},
  journal = {Southern Clinics of Istanbul Eurasia},
  year = {2025},
  pages = {57--62},
  doi = {10.14744/scie.2025.20092}
}
Kostenlos starten →